See every side of every news story
Published loading...Updated

Chiesi Global Rare Diseases Showcases Ongoing Commitment to Multiple Rare Diseases Communities at ENDO 2024 Meeting Debut

Summary by Benzinga
•  Results presented from a large, pooled database from three Phase 3 clinical trials evaluating MYCAPSSA (octreotide) for the treatment of people living with acromegaly •  Additional presentations provide insights into the validation of the Lipodystrophy Severity Scoring tool and the Chiesi Management of Acromegaly (MACRO) registry BOSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group estab…

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Friday, June 14, 2024.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.